BG Medicine (OTCMKTS:BGMD) Vs. Lucira Health (NASDAQ:LHDX) Head to Head Contrast
BG Medicine (OTCMKTS:BGMD) Vs. Lucira Health (NASDAQ:LHDX) Head to Head Contrast
BG Medicine (OTCMKTS:BGMD – Get Rating) and Lucira Health (NASDAQ:LHDX – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
BG 醫學（OTCMKTS：BGMD-獲得評級）和盧西拉健康（NASDAQ：LHDX-獲取評級）都是醫療公司，但哪個是更好的業務？我們將根據兩家公司的股息，盈利能力，估值，機構所有權，風險，收益和分析師的建議來比較兩家公司。
Insider & Institutional Ownership
內幕和機構所有權
57.0% of Lucira Health shares are held by institutional investors. 6.5% of BG Medicine shares are held by company insiders. Comparatively, 30.4% of Lucira Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Lucira 健康股份的 57.0% 由機構投資者持有。BG 醫藥股份的 6.5% 由公司內部人士持有。相比之下，露西拉健康股份的 30.4％ 由公司內部人士持有。強大的機構所有權表明，捐贈基金，對沖基金和大型資金經理認為股票將在長期內優於市場。
Profitability
盈利
This table compares BG Medicine and Lucira Health's net margins, return on equity and return on assets.
本表比較 BG 醫藥及 Lucira Health 的淨利潤率、股本回報率及資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| BG Medicine | N/A | N/A | N/A |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| BG 醫學 | N/A | N/A | N/A |
| 盧西拉健康 | -67.54% | -13.55% | -8.47% |
Analyst Recommendations
分析師推薦
This is a summary of recent ratings and recommmendations for BG Medicine and Lucira Health, as reported by MarketBeat.
這是最近對 BG 醫學和 Lucira 健康的評分和建議的摘要，據市場 Beat 報導。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BG Medicine | 0 | 0 | 0 | 0 | N/A |
| Lucira Health | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| BG 醫學 | 0 | 0 | 0 | 0 | N/A |
| 盧西拉健康 | 0 | 0 | 1 | 0 | 3.00 |
Risk and Volatility
風險及波動性
BG Medicine has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Lucira Health has a beta of 3.75, suggesting that its share price is 275% more volatile than the S&P 500.
BG 醫藥的測試值為 0.28，表明其股價比標普 500 少 72％ 的波動性。相比之下，盧西拉健康的測試值為 3.75，這表明其股價比標普 500 高出 275％ 的波動性。
Earnings & Valuation
盈利及估值
This table compares BG Medicine and Lucira Health's revenue, earnings per share and valuation.
此表比較 BG 醫藥和盧西拉健康的收入，每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BG Medicine | N/A | N/A | N/A | N/A | N/A |
| Lucira Health | $93.06 million | 0.19 | -$64.83 million | ($3.58) | -0.13 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| BG 醫學 | N/A | N/A | N/A | N/A | N/A |
| 盧西拉健康 | 九億三百零六萬元 | 0.19 | -6,483 百萬美元 | (三百五十八元) | -0.13 |
BG Medicine has higher earnings, but lower revenue than Lucira Health.
BG 醫學的收入較高，但收入低於盧西拉健康。
Summary
摘要
Lucira Health beats BG Medicine on 5 of the 8 factors compared between the two stocks.
與兩隻股票相比，Lucira 健康在 8 個因素中的 5 個因素中擊敗 BG 醫學。
About BG Medicine
關於 BG 醫學
(Get Rating)
(取得評分)
BG Medicine, Inc. is a life sciences company. It engages in developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The firm distributes products such as BGM Galectin-3 to clinical laboratories, hospitals, and healthcare providers. The company was founded in February 2000 by Jan van der Greef and is headquartered in Foxboro, MA.
BG 醫學公司是一家生命科學公司。它致力於為醫療保健提供者開發和提供創新的解決方案，以提供洞察力並改變心臟衰竭和相關疾病的臨床護理。該公司將 BGM Galectin-3 等產品分銷給臨床實驗室，醫院和醫療保健提供商。該公司由揚·范德·格雷夫成立于 2000 年 2 月，總部位於馬薩諸塞州福克斯波羅。
About Lucira Health
關於露西拉健康
(Get Rating)
(取得評分)
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Lucira Health, Inc. 是一家醫療技術公司，專注於傳染病檢 test 劑盒的開發和商業化。它開發了一個生產分子測試服務的測試平台。該公司提供 LUCIRA COVID-19 一體化檢測套件，一套 COVID-19 test 套件；並開發出甲型和乙型流感病毒 test 套件。它與艾肯化學股份有限公司簽訂了專利許可協議；與捷普股份有限公司簽訂的技術服務協議；與捷普 MSA 簽訂製造服務協議。該公司以前被稱為迪斯科技有限公司，並於 2020 年 1 月更名為盧西拉健康有限公司。盧西拉健康有限公司成立於 2013 年，總部位於加利福尼亞州埃默里維爾。
Receive News & Ratings for BG Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
接收 BG 醫學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 BG Medicine 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。